Identifying and Managing NASH in High-Risk Populations

Join leading experts as they outline why it’s crucial to look for fatty liver disease in primary care, how to identify at-risk patients, and what you can do in your practice.

Hear faculty answers to your questions in this focused live webinar, then download the slides for self study. 


  • Defining and Evaluating NAFLD and NASH
    • Identifying patients at risk
    • Understanding metabolic risk
    • To screen or not to screen?
  • Diagnosis
    • When and whom to refer
    • Interpreting FIB-4, NFS, imaging, and biopsy reports
  • Management in Primary Care
    • Lifestyle management
    • Medical treatment
    • Addressing comorbidities
  • Questions and Answers


Date / Time
Event Details


Manal F. Abdelmalek, MD, MPH

Professor of Medicine
Division of Gastroenterology and Hepatology
Duke University
Durham, North Carolina

saleh alqahtani, MD

Assistant Professor of Medicine
Department of Medicine
Medical Director, International Digestive & Liver Disease Services
Department of Gastroenterology and Hepatology
Johns Hopkins University
Baltimore, Maryland

Zobair Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD

Professor and Chairman
Department of Medicine
Inova Fairfax Medical Campus
Falls Church, Virginia

Goal Statement
The goal of this program is to improve participants’ competence in identifying and managing fatty liver disease among individuals at elevated risk and to increase awareness of NAFLD and NASH to patients who are at high risk for both diseases.

Target Audience
This program is intended for physicians, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare providers who provide care for individuals at elevated risk for fatty liver disease, including long-haul commercial drivers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Incorporate the latest data and expert guidance to identify and appropriately evaluate patients at risk for NAFLD
  • Apply appropriate methodology to diagnose and characterize NAFLD and identify patients at risk for NASH and/or fibrosis who should be referred for liver biopsy
  • Apply best practices in the management of patients with NAFLD/NASH based on guideline recommendations for lifestyle modification and medical treatment



Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation
CCO designates this live activity or enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008176-0000-19-002-L01-P) Type of Activity: Knowledge

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.